Clinical2006
Topical copper tripeptide complex (GHK-Cu) improved wound healing after CO2 laser resurfacing in a clinical study.
Comprehensive tissue repair
anecdotal
WADA Banned 9 views
Glow-Protocol-Blend
Peptide combination protocol for skin rejuvenation and radiance
WADA BANNED - Contains BPC-157 and TB-500 which are both prohibited substances in competitive sports
Overview
The Glow Protocol typically refers to a combination of peptides designed for skin improvement, often including GHK-Cu, BPC-157, and other skin-beneficial peptides. This multi-peptide approach aims to enhance collagen production, reduce inflammation, improve skin barrier function, and promote overall skin health and radiance. Protocols vary but generally focus on both oral and topical peptide applications for comprehensive skin rejuvenation.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Glow protocolGlow stackGLOW peptide stack
Status: Research compound - Multi-peptide recovery blend
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Skin rejuvenation / collagen support (GHK-Cu)Wound and tissue healing (BPC-157, TB-500/thymosin beta-4)Multi-peptide 'stack' protocols
Available Evidence
Human
No clinical trial tests the combination itself. Individual components have human data: a clinical study found topical copper tripeptide (GHK-Cu) improved healing after CO2 laser resurfacing (Arch Facial Plast Surg 2006), and GHK-Cu is used in commercial skin products; thymosin beta-4 has human trial data in cardiac and ophthalmic settings, though not within this protocol.
Animal
BPC-157 shows consistent healing effects (gastrointestinal ulcer healing, tendon/ligament repair) in rodent models; thymosin beta-4 and GHK-Cu also show tissue-repair and angiogenic effects in animal studies.
In Vitro
GHK-Cu stimulates collagen synthesis and fibroblast activity in cell culture; BPC-157 modulates angiogenesis-related gene expression in cell assays.
Uncertain
The specific combination, dosing, and skin-rejuvenation claims of the 'glow protocol' are unvalidated; reported results are largely anecdotal and driven by marketing.
Key Studies & Findings
Benefits & Effects
Side Effects & Safety
Limitations & Open Questions
The 'glow protocol' is a non-standardized, market-driven combination (typically GHK-Cu + BPC-157 + TB-500), not a regulated product or trial intervention. Evidence must be attributed to individual components; there are no data on the blend's safety, dosing, or efficacy, and BPC-157 specifically lacks robust human trials.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
Research protocols: As directed by healthcare provider - contains BPC-157, TB-500, and GHK-Cu (Research use only)
Route: SC
Half-life: Variable (depends on component peptides)
Frequently Asked Questions
What is the glow protocol?
A popular 'stack' of peptides — typically GHK-Cu, BPC-157 and thymosin beta-4 (TB-500) — marketed for skin quality, healing, and 'radiance'. It is not an approved medical treatment.
Is the glow protocol supported by clinical trials?
No trial has tested the combination. Individual components, especially GHK-Cu, have some clinical data for skin healing, but the blend itself is unvalidated.
Related Resources
Quick Facts
Molecular Weight
2667
Mechanism
Synergistic combination targeting multiple repair pathways: nitric oxide/growth factors (BPC-157), actin cytoskeleton/angiogenesis (TB-500), and collagen synthesis/anti-inflammatory (GHK-Cu)
Safety Information
Research compound only. Investigational in the United States. Sensitivity or mild sting may occur due to copper_peptide component.